AMGEN INC (1AMGN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1AMGN - US0311621009 - Common Stock
294.9 EUR
+41.1 (+16.19%)
Overall 1AMGN gets a fundamental rating of 5 out of 10. We evaluated 1AMGN against 81 industry peers in the Biotechnology industry. While 1AMGN belongs to the best of the industry regarding profitability, there are concerns on its financial health. 1AMGN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year 1AMGN was profitable.
1AMGN had a positive operating cash flow in the past year.
1AMGN had positive earnings in each of the past 5 years.
Each year in the past 5 years 1AMGN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.77%, 1AMGN belongs to the top of the industry, outperforming 85.90% of the companies in the same industry.
Looking at the Return On Equity, with a value of 72.82%, 1AMGN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
1AMGN has a better Return On Invested Capital (15.39%) than 91.03% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1AMGN is in line with the industry average of 13.22%.
The last Return On Invested Capital (15.39%) for 1AMGN is above the 3 year average (13.04%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROIC | 15.39% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
1.3 Margins
1AMGN has a better Profit Margin (19.47%) than 87.18% of its industry peers.
1AMGN's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 33.57%, 1AMGN belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
In the last couple of years the Operating Margin of 1AMGN has declined.
Looking at the Gross Margin, with a value of 72.06%, 1AMGN is in the better half of the industry, outperforming 64.10% of the companies in the same industry.
1AMGN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% |
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1AMGN is creating value.
1AMGN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, 1AMGN has less shares outstanding
1AMGN has a better debt/assets ratio than last year.
2.2 Solvency
1AMGN has a debt to FCF ratio of 4.28. This is a neutral value as 1AMGN would need 4.28 years to pay back of all of its debts.
1AMGN has a Debt to FCF ratio of 4.28. This is in the better half of the industry: 1AMGN outperforms 78.21% of its industry peers.
1AMGN has a Debt/Equity ratio of 5.45. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 5.45, 1AMGN is doing worse than 67.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Altman-Z | N/A |
ROIC/WACC1.8
WACC8.53%
2.3 Liquidity
A Current Ratio of 1.28 indicates that 1AMGN should not have too much problems paying its short term obligations.
With a Current ratio value of 1.28, 1AMGN is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
1AMGN has a Quick Ratio of 1.28. This is a bad value and indicates that 1AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
1AMGN has a worse Quick ratio (0.99) than 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
1AMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.79%, which is quite good.
1AMGN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.97% yearly.
Looking at the last year, 1AMGN shows a quite strong growth in Revenue. The Revenue has grown by 10.56% in the last year.
1AMGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.43% yearly.
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
3.2 Future
1AMGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.18% yearly.
1AMGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.22% yearly.
EPS Next Y8.22%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
EPS Next 5Y4.18%
Revenue Next Year7.43%
Revenue Next 2Y4.6%
Revenue Next 3Y3.97%
Revenue Next 5Y3.22%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
1AMGN is valuated correctly with a Price/Earnings ratio of 15.54.
Compared to the rest of the industry, the Price/Earnings ratio of 1AMGN indicates a rather cheap valuation: 1AMGN is cheaper than 85.90% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.46, 1AMGN is valued a bit cheaper.
With a Price/Forward Earnings ratio of 15.44, 1AMGN is valued correctly.
Based on the Price/Forward Earnings ratio, 1AMGN is valued cheaper than 93.59% of the companies in the same industry.
1AMGN is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.10, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.54 | ||
| Fwd PE | 15.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1AMGN is valued cheaper than 82.05% of the companies in the same industry.
1AMGN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1AMGN is cheaper than 89.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.34 | ||
| EV/EBITDA | 12.86 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1AMGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.89
PEG (5Y)2.6
EPS Next 2Y5.36%
EPS Next 3Y4.87%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.83%, 1AMGN has a reasonable but not impressive dividend return.
1AMGN's Dividend Yield is rather good when compared to the industry average which is at 10.20. 1AMGN pays more dividend than 96.15% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.32, 1AMGN pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
5.2 History
On average, the dividend of 1AMGN grows each year by 9.41%, which is quite nice.
Dividend Growth(5Y)9.41%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
17.20% of the earnings are spent on dividend by 1AMGN. This is a low number and sustainable payout ratio.
1AMGN's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP17.2%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
BIT:1AMGN (12/4/2025, 7:00:00 PM)
294.9
+41.1 (+16.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.15%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap158.76B
Revenue(TTM)35.97B
Net Income(TTM)7.00B
Analysts72
Price Target281.35 (-4.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.83% |
Yearly Dividend7.82
Dividend Growth(5Y)9.41%
DP17.2%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.96%
Min EPS beat(2)10.28%
Max EPS beat(2)11.64%
EPS beat(4)4
Avg EPS beat(4)9.04%
Min EPS beat(4)2.49%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)10
Avg EPS beat(12)4.44%
EPS beat(16)14
Avg EPS beat(16)4.21%
Revenue beat(2)2
Avg Revenue beat(2)2.59%
Min Revenue beat(2)0.68%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.17%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.21%
Revenue beat(12)4
Avg Revenue beat(12)-0.48%
Revenue beat(16)5
Avg Revenue beat(16)-0.54%
PT rev (1m)2.56%
PT rev (3m)0.42%
EPS NQ rev (1m)-7.77%
EPS NQ rev (3m)-11.23%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)0.99%
Revenue NQ rev (1m)1.1%
Revenue NQ rev (3m)1.98%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)1.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.54 | ||
| Fwd PE | 15.44 | ||
| P/S | 5.08 | ||
| P/FCF | 14.34 | ||
| P/OCF | 13.93 | ||
| P/B | 19.01 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.86 |
EPS(TTM)18.98
EY6.44%
EPS(NY)19.1
Fwd EY6.48%
FCF(TTM)20.57
FCFY6.97%
OCF(TTM)21.16
OCFY7.18%
SpS58
BVpS15.51
TBVpS-51.91
PEG (NY)1.89
PEG (5Y)2.6
Graham Number81.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROCE | 17.67% | ||
| ROIC | 15.39% | ||
| ROICexc | 17.86% | ||
| ROICexgc | 61.56% | ||
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% | ||
| FCFM | 35.46% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexgc growth 3Y3.26%
ROICexgc growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score7
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Debt/EBITDA | 2.97 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.3% | ||
| Profit Quality | 182.08% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | N/A |
F-Score7
WACC8.53%
ROIC/WACC1.8
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
EPS Next Y8.22%
EPS Next 2Y5.36%
EPS Next 3Y4.87%
EPS Next 5Y4.18%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
Revenue Next Year7.43%
Revenue Next 2Y4.6%
Revenue Next 3Y3.97%
Revenue Next 5Y3.22%
EBIT growth 1Y93.73%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year39.98%
EBIT Next 3Y10.33%
EBIT Next 5Y7.12%
FCF growth 1Y36%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y24.04%
OCF growth 3Y7.45%
OCF growth 5Y4.66%
AMGEN INC / 1AMGN.MI FAQ
Can you provide the ChartMill fundamental rating for AMGEN INC?
ChartMill assigns a fundamental rating of 5 / 10 to 1AMGN.MI.
Can you provide the valuation status for AMGEN INC?
ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (1AMGN.MI). This can be considered as Fairly Valued.
How profitable is AMGEN INC (1AMGN.MI) stock?
AMGEN INC (1AMGN.MI) has a profitability rating of 7 / 10.
What is the valuation of AMGEN INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for AMGEN INC (1AMGN.MI) is 15.54 and the Price/Book (PB) ratio is 19.01.
What is the financial health of AMGEN INC (1AMGN.MI) stock?
The financial health rating of AMGEN INC (1AMGN.MI) is 3 / 10.